Erectile Dysfunction Treatment Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025Erectile Dysfunction Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026
- Transparency Market Research
- Medical Equipments
Erectile dysfunction (ED) is a common sexual problem among men, wherein they are unable to maintain erection during copulation. The problem is age related and can be caused due to diabetes, kidney disease, prostate cancer, high blood pressure, physical injury to the prostate, penis, and pelvis. Emotional and psychological issues such as depression, stress, and anxiety can also cause erectile dysfunction. Additionally, intake of prescription medications such as antidepressants, opioid painkillers, chemotherapeutic agents, hormone drugs, amphetamines, and some sleeping pills can lead to this condition.
Rise in number of individuals experiencing erectile dysfunction is the major factor contributing to the growth of the market. According to estimates, 1 in 10 men suffer from ED globally. In the U.S. alone, more than 30 million men suffer from ED and the number is expected to rise in the next few years. Globally, men aged between 20 and 29 have around 65% chance of having ED as compared to older men aged 75 years and above, who have 77.5% probability of having ED. According to a United Nations study, the number of people aged 60 years and above was around 962 million in 2017, comprising 13% of the global population. In 2017, the number of people aged 80 years and above stood at 137 million and it is expected to triple by 2050 to reach 425 million and rise further to 909 million by 2100. The exponential rise in the geriatric population is anticipated to increase the number of patients suffering from ED which in turn is projected to drive the market. Rise in the number of individuals with diabetes is also a key factor contributing to the growth of the market. Nearly 35% to 75% men suffering from diabetes experience some degree of ED. The rapid rise in the diabetic population, which reached 422 million in 2014 (WHO estimates), is expected to increase the population of men with ED. This in turn is likely to drive demand for products used in the treatment of ED.
Pharmaceutical companies are increasingly focusing on new product development as part of their growth strategy. In November 2017, Qualigen launched Tadalafil Qualigen EFG, which is bioequivalent to Cialis marketed by Eli Lilly and used for the treatment of ED in men. The launch of Tadalafil Qualigen EFG along with its existing drug Sildenafil Qualigen has helped the company broaden its portfolio of erectile dysfunction products. In December 2016, Apricus Biosciences launched Vitaros, a novel on-demand topical cream, in Lebanon to be used in the treatment of ED. The product is marketed by Elis Pharmaceuticals Ltd. and is aimed at tapping the highly attractive ED market in the Middle East.
The global erectile dysfunction treatment market can be segmented based on treatment type, end-user, and region. In terms of treatment type, the market can be divided into drug-based treatment, device-based treatment, and others. Based on drug type, the drug-based treatment segment can be classified into avanafil, sildenafil, tadalafil, and vardenafil. In terms of end-user, the global erectile dysfunction market can be categorized into hospitals, ambulatory surgical centers, and specialty clinics.
Geographically, the global erectile dysfunction treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market due to high awareness levels among men about the disorder and launch of new products by pharmaceutical companies for the treatment of ED. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to rise in prevalence of ED because of increase in geriatric population in the region.
Key players operating in the global erectile dysfunction treatment market are Apricus Biosciences, Inc., Bayer AG, Eli Lilly and Company, Meda Pharmaceuticals, Inc., and Pfizer, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Medical Equipments
Medical DevicesNebulizers-Medical Devices Pipeline Product Landscape, 2021